Weigao Group

What Weigao Group does

Weigao Group is a China-based medical device manufacturer headquartered in Weihai, founded in 1988 and listed on the Hong Kong Stock Exchange (1066.HK) since 2004. The company operates across five business segments covering medical consumables, orthopedics, pharmaceutical packaging, interventional devices and blood management, producing items such as infusion and injection sets, COP pre-filled syringes, safety needles, orthopedic implants and interventional instruments, supported by approximately 12,000 employees and integrated polymer and needle manufacturing.

The company serves a diversified institutional customer base of more than 10,000 cooperation units, including hospitals, blood banks, orthopedic centers and pharmaceutical manufacturers in China and more than 100 international markets. Its commercial model combines direct sales to Chinese hospitals with export distribution through a dedicated overseas business department established in 2022, and it supplements organic growth with targeted acquisitions, including Argon Medical and Rad Source Technologies (2017) and New Life Medical and Zhejiang Quantum Medical (2023).

Revenue has been broadly flat over 2022-2025 while net income has compressed, indicating margin pressure from procurement pricing and product mix. Weigao is pursuing two parallel pivots: extending the orthopedic business via the 2021 WEGO ORTHO spin-off on the Shanghai STAR Market, and broadening beyond devices into therapeutics and biotech through the 2026 Baolingfu Jin nephrology joint venture and the Series A3 investment in Zhongke Aoge Biotechnology. Multiple 2024 product launches, including a Disposable Sterile Press Needle for TCM applications, signal active portfolio refresh alongside these structural moves.

Name

Weigao Group

Legal name

Shandong Weigao Group Medical Polymer Company Limited

Website

https://en.weigaogroup.com

Company type

Public

Founded year

1988

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Weigao Group is a China-based medical device manufacturer (HKEX 1066.HK) producing consumables, orthopedic implants, pharmaceutical packaging, interventional and blood management products for hospitals, blood banks and pharma manufacturers across more than 100 countries.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (33911), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Miscellaneous Plastics Products (3080)

akta.pro primary industry

Pharmaceutical & Medical Plastic Packaging Manufacturing (IMANAEAK)

akta.pro secondary industries

Rigid Pharmaceutical & Healthcare Plastic Packaging (Pill Bottles, Vials, Med-Grade Jars) (IMALAAAE), Diagnostic & Laboratory Packaging (Specimen Containers, Transport Tubes) (IMALAIAF), Medical & Pharmaceutical Thermoformed Packaging (IMANAHAB), Pharmaceutical Labels & Patient Information Packaging (Labels, IFUs, Booklets) (IMALAIAK), Pharmaceutical & Medical Device Packaging (GMP, Tamper-Evident, Cold-Chain Packs) (TLAIAGAI), Medical & Healthcare Hygiene Disposables (Patient Wipes, Underpads) (IMAMAGAF), Medical & Hygiene Disposables (Underpads, Disposable Washcloths, Bed Bath Products) (CRADALAK)

Keywords

• Medical device consumables
• Orthopedic implants
• Pharmaceutical packaging
• Blood management products
• Interventional medical devices

Headquarters

HQ city

Weihai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Consumables: Primary revenue stream from medical device consumables including infusion sets, syringes, catheters, and clinical nursing products sold to hospitals and healthcare institutions.
2. Orthopedic Products: Revenue from orthopedics segment including spine, joint, trauma, sports medicine products. WEGO ORTHO (Shandong Weigao Orthopaedic Device Co., Ltd.) is listed on SSE STAR Market.
3. Pharmaceutical Packaging: Prefilled syringes, pharmaceutical packaging consumables, and drug delivery systems for pharmaceutical companies and healthcare providers.
4. Interventional and Blood Management Products: Tumor intervention, vascular intervention products, blood collection, transfusion equipment and blood bank automation solutions.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Weigao Group manufactures and sells a broad range of single-use medical polymer consumables (infusion sets, syringes, blood collection bags, prefilled syringes) along with orthopedic implants, interventional medical devices, and pharmaceutical packaging. The company serves hospitals, clinics, and healthcare institutions as a vertically integrated domestic producer of both routine disposables and specialized surgical and interventional products.

Product overview

Weigao Group is a professional overall solution provider for the medical device industry with product lines covering medical device consumables, orthopedics, pharmaceutical packaging, intervention, and blood management. The portfolio includes five major product categories: Medical Device Products (Safe Infusion Solution, Clinical Nursing Solutions, Perioperative Solutions, Endocrine Solutions, Urinary Solution, Rehabilitation System Solution, Extracorporeal Circulation Solution), Orthopedics Products (Spine, Joint, Trauma, Sports Medicine, Orthopedic Devices, Bone Repair Material, Spinal Endoscope, PRP Treatment Consumables, Negative Pressure Drainage Consumables), Pharma Packaging Products (Prefilled Drug Delivery System, Pharmaceutical Packaging Consumables, Automatic Drug Delivery System), Interventional Products (Tumor Intervention, Vascular Intervention, Nursing Intervention), and Blood Management Products (Whole Blood Collection Consumables, Blood Transfusion Equipment). Key branded products include the WEGO LONG Series Anesthesia System with advanced ventilation modes, 4K Endoscope Camera System with digital image enhancement, Weigao Pureasy Auto-injector Pen for self-injection, COP Prefillable Syringes, Premier Posterior Spinal Fixation System, and BioPince Ultra Full Core Biopsy Instrument. The company was listed on the Hong Kong Stock Exchange in 2004 (stock code 01066.HK) and serves over 10,000 global cooperation units.

Differentiator

Problem solved

Functional benefit

Products and services

• Infusion sets Single-use medical infusion sets manufactured by Weigao Group for intravenous fluid administration in hospitals and clinical settings.
• Disposable syringes Single-use disposable syringes manufactured by Weigao Group for injection and clinical use in healthcare facilities.
• Orthopedic implants Orthopedic implants including trauma, spine, and joint products manufactured by Weigao Group for surgical orthopedic procedures in hospitals.
• Blood collection bags Blood collection and storage bags manufactured by Weigao Group for use by blood banks and hospital transfusion services.
• Prefilled syringes (COP) Cyclic Olefin Polymer (COP) prefilled syringes manufactured by Weigao Group for pharmaceutical packaging and drug delivery applications.
• Interventional medical devices Interventional medical devices manufactured by Weigao Group for minimally invasive clinical procedures.
• Full core biopsy devices Full core biopsy device systems manufactured by Weigao Group for tissue sampling in diagnostic and surgical procedures.
• Ultra-thin wall needles (27G) 27-gauge ultra-thin wall needles manufactured by Weigao Group for precision injection and clinical applications.

Quantifiable outcome

• Over 20 million patients worldwide benefit from Weigao products daily
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Baolingfu Jin (Baoling)coreStrategic or Co-development Partner · 1 May 2026Established joint venture with Weigao Group to promote nephropathy drug Nabaphosphon for treating hyperphosphatemia in China's dialysis market of over 1.18 million patients. Plans to submit medical insurance application for large-scale sales by 2027.
• Akeso BiopharmacoreStrategic or Co-development Partner · 30 September 2024Weigao Pureasy provides prefilled syringe and auto-injector pen packaging solution for Akeso's Inclisiran injection. The partnership demonstrates Weigao's capability as a one-stop solution provider for pharmaceutical drug delivery systems.
• Shandong Medical AssociationcoreStrategic or Co-development Partner · 21 August 2024Signed cooperation framework agreement for strategic partnership in major scientific and technological projects, scientific research platform construction, and professional talent cultivation. Partnership aims to build bridges for research achievement transformation and provide expert academic support.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Stryker Corporation: Global orthopedic and medical device leader; relevant comparable for Weigao's WEGO ORTHO subsidiary spanning spine, joint, trauma, and sports medicine categories.
• Shanghai Pharmaceuticals Holding: Large Chinese pharmaceutical and healthcare conglomerate with medical device operations; broader portfolio but overlapping distribution channels to Chinese hospitals and a similar domestic-substitution thesis.
• Becton, Dickinson and Company (BD): Global medical device leader with extensive syringe, infusion, and pharmaceutical packaging portfolios that directly compete with Weigao's prefilled syringe and infusion set products worldwide.

Direct peers

• Teleflex Incorporated: US-listed medical device company specializing in single-use interventional, surgical, and anesthesia products; comparable to Weigao's interventional and perioperative segments.
• Shinva Medical: Chinese medical device and pharmaceutical packaging manufacturer with overlapping sterilization, infusion, and pharmaceutical packaging products directly competing with Weigao's core consumables business.
• ICU Medical: US-listed pure-play IV therapy and medical connector manufacturer; directly comparable to Weigao's safe infusion solution product line and acquired Argon Medical operations.
• Nipro Corporation: Japanese medical device and pharmaceutical packaging company with syringe, dialysis, and glass tubing products; comparable in scale and product mix to Weigao, particularly in pharma packaging and renal/dialysis.
• Amsino International: Medical device manufacturer focused on infusion, urology, and respiratory disposables; comparable product mix to Weigao's clinical nursing and safe infusion segments with international distribution overlap.
• Mindray Medical: China's largest medical device manufacturer offering patient monitoring, in-vitro diagnostics, and medical imaging. Direct competitor across Weigao's hospital consumables and monitoring product lines in the Chinese market.

Regional players

• Fresenius Medical Care: Global leader in dialysis products and services; comparable to Weigao's blood purification subsidiary and JV activities in nephrology, particularly relevant given the Nabaphosphon dialysis partnership.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/neilniu22
• Facebookfacebook.com/weigaogroup
• LinkedInlinkedin.com/company/shandong-weigao-group-medical-polymer-co-limited-

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Weigao Group